Aligos Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $27,778 | $2,830 | $169 | $741 |
Gross Profit | 27,778 | 2,830 | -88 | 741 |
EBITDA | 1,562 | -22,377 | -19,594 | -30,783 |
EBIT | 1,307 | -22,723 | -19,851 | -31,481 |
Net Income | -1,504 | -23,040 | -19,881 | -31,537 |
Net Change In Cash | 27,778 | 2,830 | 169 | 741 |
Free Cash Flow | -24,951 | -23,197 | -21,837 | -24,538 |
Cash | 30,381 | 30,154 | 18,413 | 41,946 |
Basic Shares | 10,430 | 10,402 | 10,383 | 10,369 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $2,186 | $3,945 | $15,529 | $13,907 |
Gross Profit | 1,256 | 3,945 | 15,529 | 13,907 |
EBITDA | -22,949 | -128,258 | -83,815 | -93,905 |
EBIT | -23,879 | -130,880 | -86,884 | -97,580 |
Net Income | -24,193 | -131,211 | -87,679 | -96,046 |
Net Change In Cash | 2,186 | 3,945 | 15,529 | 13,907 |
Cost of Revenue | -105,518 | |||
Free Cash Flow | -82,940 | -80,873 | -79,016 | -80,332 |
Cash | 18,303 | 36,997 | 135,704 | 81,347 |
Basic Shares | 9,884 | 6,264 | 24,873 | 42,695 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.14 |
2026-03-31 | -$2.21 |
2025-12-31 | -$1.91 |
2025-09-30 | -$3.04 |